摘要
目的:系统评价吲达帕胺对比氢氯噻嗪治疗高血压的疗效与安全性。方法:计算机检索Cochrane图书馆、Pubmed、EM-base、SCI、中国生物医学文献数据库、中国期刊全文数据库、维普数据库、万方数据库,纳入吲达帕胺对比氢氯噻嗪治疗高血压的随机对照试验,对纳入研究进行偏倚风险分析,并对同质性结果进行Meta分析。结果:共纳入11项研究,合计1153例患者。Meta分析结果显示,吲达帕胺降低收缩压[MD=4.40,95%C(I0.53,8.27),P=0.03]和舒张压[MD=2.63,95%C(I0.63,4.63),P=0.01]显著优于氢氯噻嗪,两组比较差异有统计学意义;两组不良反应发生率比较差异无统计学意义[RR=0.62,95%CI(0.25,1.53),P=0.30]。结论:吲达帕胺降低高血压患者收缩压及舒张压疗效优于氢氯噻嗪,安全性二者相似。
OBJECTIVE：To evaluate the effectiveness and safety of indapamide versus hydrochlorothiazide in the treatment of hypertension systematically.METHODS：Databases of the Cochrane Library,Pubmed,EMbase,SCI,CBM,CNKI,VIP and Wanfang data were searched,and randomized controlled trials（RCTs） of indapamide versus hydrochlorothiazide for hypertension were included,bias risk of included studies were analyzed.Meta-analysis were carried out for homogeneity.RESULTS：11 RCTs（1 153 patients） were included,Meta-analysis indicated the differences of ΔSBP [MD=4.40,95%CI（0.53,8.27）,P=0.03] and ΔDBP [MD=2.63,95%CI（0.63,4.63）,P=0.01] between groups were significant.There were not significantly different in ADR rate in both groups [RR=0.62,95%CI（0.25,1.53）,P=0.30].CONCLUSIONS：Indapamide is better than hydrochlorothiazide in decreasing SBP and DBP of hypertensive patients,and they have similar safety.
出处
《中国药房》
CAS
CSCD
2013年第20期1886-1888,共3页
China Pharmacy
